- Home
- DXR vs ALXO Comparison
DXR vs ALXO Comparison
Compare DXR & ALXO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DXR | ALXO |
|---|---|---|
| Founded | 1970 | 2015 |
| Country | | |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 71.4M | 68.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | DXR | ALXO |
|---|---|---|
| Price | $12.40 | $2.29 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 6 |
| Target Price | ★ $25.00 | $3.42 |
| AVG Volume (30 Days) | 7.4K | ★ 772.3K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $34.39 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $7.00 | $0.40 |
| 52 Week High | $14.76 | $2.62 |
Technical Indicators
Market Signals| Indicator | DXR | ALXO |
|---|---|---|
| Relative Strength Index (RSI) | 45.27 | 65.11 |
| Support Level | $12.15 | $1.98 |
| Resistance Level | $12.90 | $2.62 |
| Average True Range (ATR) | 0.44 | 0.31 |
| MACD | 0.00 | 0.05 |
| Stochastic Oscillator | 16.67 | 73.41 |
Price Performance
Historical ComparisonAbout DXR Daxor Corporation
Daxor Corp is a medical instrumentation and biotechnology company focused on blood volume measurement. The company develops and markets the BVA-100 (Blood Volume Analyzer), the first diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms in a broad range of medical conditions.
About ALXO ALX Oncology Holdings Inc.
ALX Oncology Holdings Inc is a clinical-stage immuno-oncology company focused on helping patients fight cancer by developing a pipeline of product candidates based on expertise in protein engineering and oncology led by the CD47 blocker, evorpacept, currently in phase 1 and 2 clinical trials. Cancer cells leverage CD47, a cell surface protein, as a don't eat me signal to evade detection by the immune system. The company is developing a next-generation checkpoint inhibitor designed to have a high affinity for CD47 and to avoid the limitations caused by hematologic toxicities inherent in other CD47 blocking approaches.